{"id":"NCT01962441","sponsor":"Gilead Sciences","briefTitle":"SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection","officialTitle":"A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-24","primaryCompletion":"2015-01-07","completion":"2016-07-07","firstPosted":"2013-10-14","resultsPosted":"2016-02-05","lastUpdate":"2017-06-20"},"enrollment":601,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"SOF","otherNames":["Sovaldi®","GS-7977","PSI-7977"]},{"type":"DRUG","name":"RBV","otherNames":[]},{"type":"DRUG","name":"Peg-IFN","otherNames":[]}],"arms":[{"label":"SOF+RBV 16 weeks","type":"EXPERIMENTAL"},{"label":"SOF+RBV 24 weeks","type":"EXPERIMENTAL"},{"label":"SOF+RBV+Peg-IFN 12 weeks","type":"EXPERIMENTAL"},{"label":"Retreatment Substudy","type":"EXPERIMENTAL"}],"summary":"This study will assess the efficacy, safety, and tolerability of 16 or 24 weeks of sofosbuvir (Sovaldi®; SOF) + ribavirin (RBV), and 12 weeks of SOF+RBV+ pegylated interferon (Peg-IFN) in treatment-naive and treatment-experienced adults with chronic genotype 3 hepatitis C virus (HCV) infection, and treatment-experienced adults with cirrhosis and chronic genotype 2 HCV infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF+RBV 16 Weeks","deltaMin":71.9,"sd":null},{"arm":"SOF+RBV 24 Weeks","deltaMin":85.4,"sd":null},{"arm":"SOF+RBV+Peg-IFN 12 Weeks","deltaMin":92.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":11},"locations":{"siteCount":78,"countries":["United States","Australia","Canada","New Zealand","United Kingdom"]},"refs":{"pmids":["26248087"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":196},"commonTop":["Fatigue","Headache","Insomnia","Nausea","Rash"]}}